(TheNewswire)
Calgary , Alberta – TheNewswire - September 21 , 2023 – nDatalyze Corp. (“NDAT” or the“Corporation”) (CSE:NDAT) (OTC:NDATF) announces that it hasreceived multiple expressions of interest from highly-qualifiedpotential Principal Investigators (“PI”) for itspreviously-announced, Mitacs-sponsored Clinical Study. The potentialPIs to date include qualified persons in the fields of Psychiatry andAI/Machine-Learning. The Clinical Study is beingundertaken to test, calibrate and validate the machine-learning based,YMI Clinical Decision Support System(“CDSS”) and will be funded in combinationwith Mitacs. Mitacs typically shares costs, but the ratio cannot beknown until the PI sets out the process, protocols, and budget. Details will be released once the Clinical Studyis formalized. Interested parties canview the project outline at https://www.mitacs.ca/en/opportunity/7921/view . YMI is currently a fully operational online system based onthe Corporation’s proprietary Reference Database andMachine-Learning algorithms. Those who wish to try the system at nocharge are urged to contact jimd@ndatalyze.com.
James Durward, President, states “It’s wonderful toexperience the excitement of these highly qualified experts and I lookforward to working with the selected parties during the ClinicalStudy. In my opinion, machine-learning has the potential tofundamentally change the way mental conditions are diagnosed andtreated; promising a significant reduction of mis/overdiagnoses andattendant follow-on mis/overprescriptions that contribute to theclogged mental health system. The recentgroundswell supporting proactive mental health reinforces our decisionto focus on making YMI available to the medical community as soon aspractically possible.”
The Corporation firmly believes that NDATs extremelylow capitalization compared to its peers presents an outstandinginvestment opportunity for those investors active in the mental healthspace. Some p eerexamples:
Company | Ticker | Market Cap | Products/ Services | Recent Activities |
| NASDAQ: TALK | $295mm (US$) | ?Online therapy | launched Talkspace, a product providing a number of offerings thathelps teams, executives and managers to build mental wellness andemotional quotient. Large revenues |
| CSE: PMED OTC: PMEDF | $13mm (CAD) | ?predictive health-related conditions | Looking for partners and financing – no revenue |
| CSE: AIAI OTC: AINMF | $21mm (CAD) | ?AI-assisted Clinical trial efficiency software designed to increaseclinical trial success rate | Multiple financings to support research and G&A expenses. Minimalrevenue |
| CSE: THNK | $19mm (CAD) | ? offers innovative tools designed to deliver evidence-based bestpractices to clinicians | Announced that its Pharmapod system was selected by an Ontariolong-term care chain. Significant revenues and multiple debtfinancings. |
| CSE: NDAT | $ 3mm (CAD) | ?YMI mental health Clinical Decision Support System | nDatalyze finalized the supervised ML algorithms for seven mentalhealth conditions (personality disorder, anxiety, alcoholism,post-traumatic stress disorder (PTSD), bipolar disorder,obsessive-compulsive disorder (OCD) and depression) and completed MLtesting. Minimal revenue. Currently arranging a Clinical Study torefine, calibrate and validate the system. |
About YMI: YMIuses evidence-based, objective data from whole life experiences topredict individual mental states over time and applies this knowledgetowards a fuller understanding of how mental health develops and to improve mental wellbeing. YMI combinesmachine-learning with a proprietary Reference Database that contains>1200 person’s genetic expressions, childhood environment,habits, phobias, lived experiences and lifestyle to generate apersonalized graphic report predicting an individual’spredisposition toward a variety of common mental conditions, bothcurrent and forward in time.
For Further Information, PleaseContact:
James Durward, President and CEO
Telephone: (403) 689-3901
Email: jimd@ndatalyze.com
nDatalyze Website: https://www.ndatalyze.com
YMI Website: https://ymihealth.ca
Neither the Canadian Securities Exchange nor itsRegulation Services Provider (as that term is defined in the policiesof the Canadian Securities Exchange) accepts responsibility for theadequacy or accuracy of this release. This news release does notconstitute an offer to sell or a solicitation of an offer to sell anyof the securities in the United States. The securities have not beenand will not be registered under the United States Securities Act of1933, as amended (the "U.S. Securities Act") or any statesecurities laws and may not be offered or sold within the UnitedStates or to U.S. Persons unless registered under the U.S. SecuritiesAct and applicable state securities laws or an exemption from suchregistration is available.
The information in this news release includes certaininformation and statements about management's view of future events,expectations, plans and prospects that constitute forward lookingstatements. These statements are based upon assumptions that aresubject to significant risks and uncertainties. Because of these risksand uncertainties and as a result of a variety of factors, the actualresults, expectations, achievements or performance may differmaterially from those anticipated and indicated by theseforward-looking statements. Any number of factors could cause actualresults to differ materially from these forward-looking statements aswell as future results. Although the Corporation believes that theexpectations reflected in forward looking statements are reasonable,it can give no assurances that the expectations of any forward-lookingstatements will prove to be correct. Except as required by law, theCorporation disclaims any intention and assumes no obligation toupdate or revise any forward-looking statements to reflect actualresults, whether as a result of new information, future events,changes in assumptions, changes in factors affecting suchforward-looking statements or otherwise.
Copyright (c) 2023 TheNewswire - All rights reserved.